Therapeutic potential of yeast killer toxin-like antibodies and mimotopes

31Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

This review focuses on the potential of yeast killer toxin (KT)-like antibodies (KTAbs), that mimic a wide-spectrum KT through interaction with specific cell wall receptors (KTR) and their molecular derivatives (killer mimotopes), as putative new tools for transdisease anti-infective therapy. KTAbs are produced during the course of experimental and natural infections caused by KTR-bearing micro-organisms. They have been produced by idiotypic vaccination with a KT-neutralizing mAb, also in their monoclonal and recombinant formats. KTAbs and KTAbs-derived mimotopes may exert a strong therapeutic activity against mucosal and systemic infections caused by eukaryotic and prokaryotic pathogenic agents, thus representing new potential wide-spectrum antibiotics. © 2004 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.

Cite

CITATION STYLE

APA

Magliani, W., Conti, S., Salati, A., Vaccari, S., Ravanetti, L., Maffei, D. L., & Polonelli, L. (2004, October). Therapeutic potential of yeast killer toxin-like antibodies and mimotopes. FEMS Yeast Research. https://doi.org/10.1016/j.femsyr.2004.06.010

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free